FLT3 and acute myeloid leukemia: In the phase 1, multicenter, open-label, dose-escalation, and dose-expansion study of ivosidenib NCT02074839, involving 179 patients, mutations in receptor tyrosine kinase (RTK) pathways (including NRAS, KRAS, PTPN11, KIT, and FLT3) were associated with a lower likelihood of clinical response to ivosidenib monotherapy in R/R AML.